Subscription ratio of 135.6 to 1
New shares to be listed on the 30th

Samsung Biologics has completed a public offering of shares worth approximately KRW 2.7 trillion as part of its paid-in capital increase, attracting more than KRW 11 trillion in subscription deposits. Funding for its acquisition of the Polypeptide Group to enter the peptide business has also effectively been secured.

A view of Samsung Biologics Plant 4 in Yeonsu-gu, Incheon. Samsung Bio

A view of Samsung Biologics Plant 4 in Yeonsu-gu, Incheon. Samsung Bio

View original image

On the 16th, Samsung Biologics said the public offering, held over two days on November 12 and 13, drew applications for 9,745,071 shares, resulting in a subscription ratio of 135.6 to 1. Subscription deposits totaled KRW 11.4407 trillion, the largest amount ever for a rights offering that also included a public offering. At the new share issue price of KRW 1.174 million, investors would need to put up approximately KRW 160 million to be allocated one share.


The public offering was for the 71,854 shares left over after subscriptions by existing shareholders and the employee stock ownership association. In the subscriptions by existing shareholders and the employee stock ownership association held on November 9 and 10, applications were received for 2,198,146 of the 2.27 million shares issued, or 96.8%.


Samsung Biologics will issue 2.27 million common shares at KRW 1.174 million per share, raising a total of KRW 2.665 trillion. The proceeds will be used to acquire the Polypeptide Group, a global peptide contract development and manufacturing organization (CDMO). In July, Samsung Biologics announced the acquisition for CHF 1.46 billion, equivalent to approximately KRW 2.7 trillion at the time of the announcement. It was the largest acquisition in the history of the Korean pharmaceutical and biotech industries.


In the recently completed tender offer, shareholders tendered 97.98% of the shares. Samsung Biologics plans to secure 100% ownership through a compulsory acquisition and other means. The company aims to expand its business into peptides, adding to its existing areas of antibody drugs, messenger RNA (mRNA), and antibody-drug conjugates (ADCs).



The paid-in capital increase will be completed after payment for the shares on the 17th and the listing of the new shares on the 30th.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing